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Founded 35 years ago, the European Organisation for Research and Treatment of
Cancer Genito-Urinary Cancers Group (GU Group) has carried out a total of 99
phase I, II and III clinical trials in the ﬁelds of bladder, prostate, kidney, testicular
and penile cancer. Meta-analyses have answered clinically important questions that
the individual studies could not answer by themselves.
From its very beginning, the GU Group has adopted a multidisciplinary approach,
with collaboration among urologists, medical oncologists, radiation oncologists,
pathologists and biostatisticians. It has also had a very successful collaboration with
the EORTC Radiation Oncology Group and with national organizations such as the
UK Medical Research Council.
The results of their work, which remain standards in the ﬁeld today, have directly
led to major worldwide improvements in day to day clinical practice and have been
incorporated into treatment guidelines such as those of the European Association of
Urology.
The group’s intention is to build on this important legacy and to continue to develop
and recruit to the multicenter, international randomized studies that have been their
hallmark.Their primary aimwill be to focus on clinical trials that investigate strategic
therapeutic questions and which have the potential to change medical practice and
improve our understanding of urologic malignancies. This includes studies with
strong translational research components, prospective clinico-genomic and cancer
biology/biomarker data and clinical trials addressing rare tumor types. To carry this
strategy into the future, the contribution of individual clinicians, collaborative cancer
trial groups and pharmaceutical companies is of fundamental importance.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The European Organisation for Research and Treat-
ment of Cancer (EORTC) Genito-Urinary Cancers Group
(GU Group) was founded 35 years ago in August 1976 by
M. Pavone Macaluso (IT) and P. Smith (UK), the latter
being the ﬁrst of twelve chairmen who have guided
the group since its beginning. 1 During this time period,
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the GU Group has carried out a total of 99 phase I, II
and III clinical trials in the ﬁelds of bladder (35 trials),
prostate (30 trials), kidney (18 trials), testicular (15 trials)
and penile cancer (1 trial). Meta-analyses have also
been carried out to answer a number of important
questions that the individual studies could not answer
by themselves. The work of the GU Group has directly
contributed to changes in clinical practice worldwide
and has been incorporated into various treatment
guidelines such as those of the European Association of
Urology (EAU).
From its very beginning, the GU Group has adopted
a multidisciplinary approach, as evidenced by the
collaboration among urologists, medical oncologists,
radiation oncologists, pathologists and biostatisticians.
It has also had a very successful collaboration with the
EORTC Radiation Oncology Group in conducting large
phase III trials in prostate cancer, and with various
national organizations such as the UK Medical Research
Council for testicular and bladder cancer. An intergroup
collaboration with groups funded by the US National
Cancer Institute (NCI) in the USA has also been in place.
2. Achievements
Bladder cancer and prostate cancer have each accounted
for approximately one third of the studies that the
GU Group has conducted. Some of the most important
achievements by disease site are summarized below.
2.1. Urothelial carcinoma of the bladder and urinary tract
The GU Group has been active in both non muscle
invasive (superﬁcial) bladder cancer and advanced
bladder/urinary tract cancer, with trial results and meta-
analyses having had a direct impact on day to day clinical
practice.
2.1.1. Non muscle invasive bladder cancer (NMIBC)
The GU Group has carried out 11 randomized phase III
trials comparing different adjuvant intravesical and oral
treatments after transurethral resection of the bladder
tumor (TURBT). Together with the EORTC Headquarters,
the GU Group has also published four meta-analyses
and one combined analysis comparing different adjuvant
regimens.
Randomized studies, meta-analyses and combined
analyses of the group have shown that:
• Intravesical chemotherapy delays the time to ﬁrst
recurrence after TURBT but not the time to progres-
sion. 2
• No individual intravesical chemotherapy regimen has
been identiﬁed as being superior to another (trials
30751, 30782, 30791). 3−5
• A single immediate post TURBT instillation of chemo-
therapy reduces the risk of recurrence by 39%. 6,7
• The optimal schedule and duration of intravesical
chemotherapy after an immediate post TURBT instil-
lation remains unknown (trials 30831, 30832). 8,9
• In intermediate and high risk patients (papillary
tumors and/or carcinoma in situ), intravesical BCG is
superior to intravesical chemotherapy in delaying the
time to recurrence, time to progression and death due
to bladder cancer but only when maintenance BCG is
given (trials 30845, 30906, 30911). 10−13
• Intravesical BCG has more local and systemic side
effects than intravesical chemotherapy, however main-
tenance BCG is not associated with increased long term
toxicity (trial 30911). 14,15
• Intravesical BCG side effects do not predict its efﬁcacy
(trial 30911). 16
• No difference in efﬁcacy between BCG strains could be
identiﬁed. 13
Results of trial 30962 comparing two different BCG
doses (full dose versus one third dose) and durations
of treatment (one year maintenance versus three years
maintenance) in more than 1300 stage TaT1 patients will
be available in 2012.
An internationally recognized prognostic factor scoring
system (EORTC Risk Tables) based on 2596 patients from
seven EORTC studies has been developed to predict a
patient’s probability of recurrence and progression using
software available on the EORTC website. This unique
resource allows the choice of treatment and frequency
of follow up to be tailored according to the individual
patient’s prognosis. 17
The GU Group has demonstrated a large variability
in the recurrence rate at the ﬁrst follow up cystoscopy
between institutions. 18 These results have highlighted
the need for stricter surgical quality control and for
pathology review, which is essential for the accurate
staging of high risk T1G3 patients. 19
The GU Group has thus played a major international
role in establishing Level 1 evidence to guide the
treatment of patients with NMIBC, leading to major
improvements in routine day to day care, especially in
establishing a single immediate post TURBT instillation
of chemotherapy 6,7 and the long-term superiority of BCG
to compared chemotherapy 12 as cost effective standards.
Through this evidence base and the associated EORTC
NMIBC risk calculator, the GU Group has played a leading
role in the development of the European Association
of Urology (EAU) Guidelines for the treatment of this
disease, the most expensive of all cancers. 20
2.1.2. Locally advanced bladder cancer (muscle invasive)
The long-term results of the EORTC/MRC intergroup
randomized study 30894/BA06 have conﬁrmed a statis-
tically signiﬁcant prolongation of overall survival with
cisplatin–methotrexate–vinblastine (CMV) neo-adjuvant
chemotherapy, with a reduction of 16% in the risk
of death. This study in 976 patients, the largest ever
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in locally advanced bladder cancer, has established
neo-adjuvant chemotherapy followed by deﬁnitive local
therapy (radical cystectomy or radiotherapy) as a state
of the art treatment for patients with muscle invasive
bladder cancer. 21
EORTC intergroup study 30994 comparing immediate
versus deferred chemotherapy after radical cystectomy is
still in follow up. This study, the largest ever randomized
study of adjuvant chemotherapy after cystectomy, will
provide high level evidence concerning the possible
beneﬁt of adjuvant chemotherapy.
2.1.3. Advanced urothelial cancer of the urinary tract
(unresectable and metastatic)
In advanced urinary tract urothelial carcinoma, three
EORTC randomized studies have been carried out:
• High dose M-VAC with G-CSF was shown to be
superior to classical M-VAC with respect to both
efﬁcacy and toxicity, thus establishing high dose M-VAC
as a standard treatment for advanced disease (trial
30924). 22
• The only randomized trial comparing two carboplatin-
based regimens in patients unﬁt for cisplatin has
shown that gemcitabine/carboplatin is the preferred
regimen based on its favorable toxicity proﬁle (trial
30986). 23
• In previously untreated patients, the addition of a
taxane to the standard regimen of gemcitabine and
cisplatin failed to provide a statistically signiﬁcant
improvement in overall survival, however in a post hoc
subgroup analysis, a 19% reduction in the risk of death
in patients with bladder as the site of the primary
tumor was observed (trial 30987) [J Clin Oncol, in press].
2.2. Prostate cancer
GU group prostate cancer (PCa) studies have led to 128
peer-reviewed publications from 1986 to 2010. Research
has focused on the role of hormone therapy in advanced
and metastatic PCa and on the beneﬁt of adjuvant
external beam radiation therapy (EBRT). Other studies
have also investigated new therapies in castration-
resistant PCa. Some of the most important studies are
summarized in the following.
2.2.1. Metastatic prostate cancer
The group has demonstrated the limited beneﬁt of
Maximum Androgen Blockade (MAB) with non steroidal
anti-androgens, the lack of beneﬁt of MAB with
cyproterone acetate (CPA) and the cardiovascular toxicity
of estrogens:
• MAB (monthly goserelin acetate and ﬂutamide) sig-
niﬁcantly increases progression-free, overall and PCa-
speciﬁc survival compared to orchiectomy (trial 30853),
but there was no difference between orchiectomy
and buserelin combined with CPA, taken either
continuously or during only 2 weeks (trial 30843). 24,25
• Study 30805, comparing orchiectomy, orchiectomy plus
CPA, and daily stilboestrol (DES) (1mg) showed no
difference in efﬁcacy, but identiﬁed the cardiovascular
toxicity of DES. 26
Prior to study 30805, the very ﬁrst GU Group trials in pa-
tients with either metastatic or locally advanced prostate
cancer compared DES to CPA to medroxyprogesterone
acetate (MPA) (trial 30761) or to Estracyt (trial 30762). MPA
was found to be inferior to CPA and to DES, however there
was no difference in efﬁcacy between DES and Estracyt.
Although the MAB studies suggest that ﬂutamide may
be superior to CPA, no difference in efﬁcacy was found
in metastatic patients with favorable prognostic factors
(trial 30892). 27
In poor-prognosis metastatic prostate cancer, the
administration of mitomycin C after orchiectomy had
signiﬁcant toxicity, a negative impact on quality of life
and decreased overall survival (30893). 28
Four randomized studies have been carried out in hor-
mone refractory prostate cancer, studying mitomycin C
versus Estracyt (trial 30865), ﬂutamide versus prednisone
(trial 30903), strontium chloride versus palliative ﬁeld
local radiotherapy (trial 30921) and satraplatin plus
prednisone versus prednisone alone (trial 30972). Only
satraplatin appeared to be more effective with acceptable
toxicity, 29 leading to further studies.
2.2.2. Locally advanced prostate cancer
The GU Group challenged the conventional wisdom
that every advanced PCa patient should be treated
immediately with androgen deprivation therapy (ADT).
Two important trials studied long-term ADT in men
with locally advanced PCa who were unﬁt for radical
treatment:
• Study 30891 compared immediate versus deferred
ADT in 985 patients with T0−4N0−2M0 PCa. The
overall survival results favored immediate treatment
(HR=1.25), seemingly due to fewer non PCa deaths.
However neither time to castration-resistant disease,
nor PCa-speciﬁc survival differed. Further investiga-
tions suggested that the greatest beneﬁt of immediate
ADT in older patients was seen in those with an initial
PSA> 50ng/ml and/or with a rapid PSA doubling time
(<12 months), i.e. in patients who are at a higher risk
of dying from PCa, but that older patients with initial
PSA< 50 ng/ml and a slow PSA doubling time could be
spared the burden of immediate ADT. 30
• Study 30846 compared early versus delayed ADT when
radical prostatectomy was aborted after ﬁnding posi-
tive lymph nodes. After 13 years of follow-up, overall
and PCa-speciﬁc survival on both arms appeared
similar, but non-inferiority could not formally be
shown. 31
Together with the EORTC Radiation Oncology group,
the GU Group demonstrated that long-term adjuvant
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hormone therapy beneﬁts locally advanced PCa patients
treated by external beam radiotherapy (EBRT):
• Study 22863 demonstrated that added to EBRT, 3 years
of ADT increased 5-year overall and PCa-survival
by 15%. The beneﬁt was maintained at 10 years. 32
• Later in the same setting, study 22961 compared
6 months ADT to 3 years ADT and showed a 5% greater
5-year overall survival with the longer ADT regimen. 33
The EORTC GU and Radiation Oncology groups also
investigated the beneﬁt of adjuvant radiotherapy in
patients with adverse pathological factors after radical
prostatectomy:
• Study 22911 randomized 1005 men between surveil-
lance and immediate EBRT. The initial reports showed
that EBRT signiﬁcantly improved biochemical and loco-
regional progression-free survival at 5 years. However
with 10 years median follow-up, the study has not
shown a beneﬁt in time to metastases or duration of
survival. 34
The GU Group has thus carried out clinically important,
practice-changing prostate cancer studies, the results of
which remain referenced standards in the ﬁeld today.
2.3. Renal cell carcinoma
The GU group has performed 16 studies in kidney cancer,
including seven phase III trials comparing different
surgical approaches, multimodality treatment concepts
integrating surgery and medical treatment and systemic
therapies for locally conﬁned and advanced renal cell
carcinoma. In addition, a major phase III trial is
ongoing to investigate the sequence of cytoreductive
nephrectomy and systemic therapy in metastatic renal
cell carcinoma.
Landmark randomized studies of the GU group have
shown that:
2.3.1. For locally conﬁned kidney cancer
• Nephron sparing surgery is safe and not inferior to
radical nephrectomy in patients with a solitary, 5 cm
T1−T2N0M0 renal cell carcinoma (trial 30904). 35
• After proper preoperative staging, the incidence of
unsuspected lymph-node metastases is low (4.0%)
and a complete node dissection in conjunction with
radical nephrectomy does not improve survival (trial
30881). 36
• Adjuvant combination therapy with interferon (IFN)
alfa, interleukin-2, and 5-FU is associated with signiﬁ-
cant toxicity and does not improve overall or disease-
free survival in patients at high risk of progression after
nephrectomy (trial 30955). 37
2.3.2. For metastatic kidney cancer
• Progression-free and overall survival for progressive
patients treated with IFN-alpha-2a plus 13-CRA were
signiﬁcantly longer compared with patients on IFN-
alpha-2a alone (trial 30951). 38
• Cytoreductive radical nephrectomy before IFN-based
immunotherapy substantially delays time to progres-
sion and improves duration of survival of metastatic
patients with a good performance status (trial 30947).
These results were consolidated in a combined analysis
of data from this study and data from the SWOG. 39,40
• Combination therapy with IFN alfa-2a, interleukin-2,
and ﬂuorouracil does not improve overall or progres-
sion-free survival compared with IFN alfa-2a alone
(trial 30012). 41
• Combination IFN gamma and IFN alpha2-c is not more
effective than IFN alpha2-c alone (trial 30885). 42
The GU group has undertaken large randomized
phase III trials in the ﬁeld of renal cancer, generating
Level 1 evidence to facilitate management in this ﬁeld.
This evidence base has enabled the development and
international dissemination of techniques establishing
the place of nephron sparing surgery, lymph node
dissection and cytoreduction in renal cancer surgery
and has determined the effectiveness of combination
immunotherapeutic regimens in metastatic disease.
2.4. Testicular cancer/germ cell tumors
Three trials were initially carried out in non seminoma-
tous germ cell tumors (NSGCT):
• Trial 30795 compared high-dose to low-dose vinblas-
tine in cisplatin–vinblastine–bleomycin (PVB) induction
chemotherapy. 43
• In trial 30824, four cycles of bleomycin, etoposide and
cisplatin (BEP) were compared to four cycles of EP in
good-prognosis patients and four cycles of BEP were
compared to alternating PVB/BEP in poor-prognosis
patients. 44,45
• Trial 30873 compared four cycles of BEP to four cycles
of VIP in intermediate-prognosis patients. 46
A number of germ cell tumor trials have been carried
out together with the UK Medical Research Council
(MRC):
• In poor-prognosis patients, six cycles of sequential
BOP/VIP-B were compared to BEP/EP with and without
G-CSF (trial 30895). 47,48
• In good-prognosis patients, four cycles of BEP were
compared to BEC (carboplatin) (trial 30896). 49
• Trial 30941 attempted to show the non-inferiority of
3 versus 4 cycles of BEP and a 3-day versus a 5-day
schedule of BEP in good-prognosis patients. 50,51
The following lessons have been learned from these
studies:
In good-prognosis patients, BEP is more effective
than EP but is associated with more pulmonary and
neurotoxicity. Carboplatin is inferior to cisplatin and
cannot replace it. Treatment can be given in 3 cycles
rather than in 4 and in 3 days rather than in 5 days.
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In intermediate- and poor-prognosis patients, other
treatment regimes such as PVB/BEP, VIP, and BOP/VIP-B
were not shown to be more effective than BEP but
were more toxic, especially in relation to hematological
toxicity. G-CSF improved dose delivery but not efﬁcacy
and hence its use with BEP/EP is not justiﬁed.
More recently, the results of two important randomized
studies have become available:
• A randomized phase III study of sequential high-dose
cisplatin/etoposide/ifosfamide plus stem cell support
versus BEP in patients with poor-prognosis germ cell
cancer (trial 30974) has been completed. This study
showed that high-dose chemotherapy did not improve
the outcome in poor-prognosis patients. 52
• A randomized phase II/III study of paclitaxel-BEP versus
BEP in patients with intermediate prognosis germ
cell cancer (trial 30983) showed that there was no
signiﬁcant difference in the primary endpoint, the
duration of progression free survival, based on an
intent to treat analysis. 53
The GU Group also contributed to MRC trials that
assessed the optimal adjuvant treatment for stage I
seminoma patients. One trial (MRC TE18/EORTC 30942)
was designed to compare the efﬁcacy and acute and
long-term morbidity of standard radiotherapy with 30Gy
in 15 fractions versus 20Gy in 10 fractions whereas the
other trial (MRC TE19/EORTC 30982) assessed the non-
inferiority of single-agent carboplatin to radiotherapy.
Optionally, patients allocated radiotherapy within TE19
could be randomly assigned between 20 and 30Gy, with
the intent that these patients could also contribute
to the question addressed by TE18 at a later date.
TE18 showed that 20Gy of irradiation is unlikely to
produce relapse rates more than 3% higher than the
standard 30Gy. 54 Reductions in morbidity with shorter
treatment enable patients to return to work more rapidly.
Trial TE19 has shown the non-inferiority of a single
course of carboplatin at preventing relapses compared to
radiotherapy in the treatment of stage I seminoma, with
a reduced risk of second cancers. 55 A combined analysis
of TE10, TE18 and TE19 has provided support for the use
of either radiation therapy or carboplatin as adjuvant
treatment for stage I seminoma. 56
Together with the MRC, the studies of the GU
Group have been instrumental in deﬁning the optimal
treatment in testicular cancer patients. To date, it has
not been possible to ﬁnd a therapeutic regimen which is
superior to BEP for NSGCT.
3. Future perspectives and strategy
The GU Group has made a signiﬁcant and internationally
important contribution to the practice of Urological
Oncology. It is the group’s intention to build on this
important legacy in the future and to continue to develop
and recruit to multi-center, international randomized
studies that have been the hallmark of this clinical trials
group.The group’s primary aimwill be to focus on clinical
trials that investigate strategic therapeutic questions and
which have the potential to change medical practice and
to improve our understanding of urologic malignancies.
To this end the GU Group will follow the general EORTC
Scientiﬁc Strategy, encompassing design and recruitment
to phase III academic trials aimed at changing the
standard of care, studies with strong translational
research components, including prospective clinico-
genomic and cancer biology/biomarker data and clinical
trials addressing rare tumor types.
In designing and coordinating clinical trials, current
and emerging difﬁculties need to be acknowledged,
most notably the increasing breadth of the statutory
legislation required for pan-European studies. The
burgeoning requirements for patient information, trial
documentation and the differences in regulations
regarding sample collection for translational research
bring genuine difﬁculties for trial groups and clinicians
alike. The corollary of this is that the complexities, cost
and time taken to develop and run modern RCTs have
substantially increased. Faced with these difﬁculties,
it would be easier for clinicians to take the path of
least resistance and accept the status quo. However,
these issues require a stiffer resolve and the importance
of attempting to answer the questions at hand is
exempliﬁed in this overview, where the inﬂuence of
well-conducted RCTs on modern day practice is clear to
see. RCTs run by academic groups such as the EORTC
GU Cancers Group must remain the keystone in the
development of modern cancer care. This academic
approach is the most appropriate for evaluating optimal
new therapies, their sequencing, targeting and their
combination with other agents.
The future multidisciplinary ethos of the GU Group will
continue to involve urologists, medical oncologists and
radiotherapists working in tandem with pathologists,
radiologists, translational scientists and biostatisticians.
Planned collaborations will incorporate biomarker and
imaging consortia in both prospective data gathering and
retrospective archive analysis. This approach is reﬂected
in translational research programs currently being
integrated into GU Group trial 30073, investigating the
sequencing of cytoreductive nephrectomy and targeted
therapy in primary metastatic RCC. This study will
collect tissue in more than 400 patients to investigate
prognostic and predictive biomarkers synchronously
with sequential state of the art imaging sub-studies. This
integrated approach will be directed to other key areas
in Urological Oncology such as the management of
high-risk localized prostate cancer, new approaches to
the management of metastatic bladder and prostate
cancers and imaging and treatment stratiﬁcation in testis
cancer.
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To carry this strategy into the future, and to build on the
achievements of the GU Group over the last 35 years, the
engagement and contribution of individual clinicians,
collaborative cancer trial groups and pharmaceutical
companies is of fundamental importance. Considering
this we should perhaps reﬂect on the words contained in
Theodore Roosevelt’s 1903 presidential address, in which
he said that “the best prize that life offers is the chance
to work hard at work worth doing”. The achievements of
the last 35 years have undoubtedly been hard earned but
they have certainly been worthwhile. It is important that
this work continues.
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